Novo Nordisk Up 0.77% After Bank Backs European Pharma as AI Alternative
NVO•A leading global investment bank upgraded European pharmaceutical stocks as a defensive play against high-multiple AI equities, citing stable dividend yields and resilient cash flows. Novo Nordisk shares rose 0.77% following the endorsement, with analysts highlighting attractive valuations relative to technology peers.
1. Bank Endorses European Pharma
A leading global investment bank recommended European pharmaceutical companies as a ‘cleaner alternative’ to high-growth AI equities, emphasizing defensive attributes. The firm upgraded ratings on major names, including Novo Nordisk, pointing to stable dividend yields, resilient cash flows and more attractive valuations compared with technology peers.
